UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000055438 |
|---|---|
| Receipt number | R000063350 |
| Scientific Title | A systematic review of mitochondrial transplantation therapy on cancer care |
| Date of disclosure of the study information | 2024/09/06 |
| Last modified on | 2024/09/06 04:31:13 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A systematic review of mitochondrial transplantation therapy on cancer care
Acronym
A systematic review of mitochondrial transplantation therapy on cancer care
Scientific Title
A systematic review of mitochondrial transplantation therapy on cancer care
Scientific Title:Acronym
A systematic review of mitochondrial transplantation therapy on cancer care
Region
| North America |
Condition
Condition
Cancer, Cachexia, Sarcopenia, Muscle injury
Classification by specialty
| Hematology and clinical oncology |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
The purpose of this systematic review is to summarize current evidence from in vitro and in vivo studies on mitochondrial transplantation as a novel therapeutic strategy for cancer care and for treating sarcopenia and muscle injury associated with cachexia.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Others
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Biological or physiological measures of the cancer, cachexia, or sarcopenia/muscle injury
Key secondary outcomes
Safety
Base
Study type
Others,meta-analysis etc
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
P: Animals suffering from cancer, cachexia, or sarcopenia/muscle injury that can be induced as cachexia-related symptoms or Cancer cell lines
I: Intravascular injection, or direct injection into the region of cancer or sarcopenia/muscle injury in in vivo study with isolated mitochondria. Direct transplantation/co-culture in in vitro study with isolated mitochondria.
O: biological or physiological measures of the cancer, cachexia, or sarcopenia/muscle injury
S: RCT, other intervention studies, cohort studies, animal studies, cancer cell line studies
1. Studies published in peer-reviewed journals.
2. Studies published as research papers which enabled to obtain a full text.
3. Journals written in English.
Key exclusion criteria
1. Studies that used a mesenchymal stem cell-mediated transfer of mitochondria as a transfer method
Target sample size
Research contact person
Name of lead principal investigator
| 1st name | Kei |
| Middle name | |
| Last name | Hayashida |
Organization
Feinstein Institutes for Medical Research
Division name
Laboratory for Critical Care Physiology
Zip code
11030
Address
350 Community Dr, Manhasset, NY
TEL
1-516-562-1305
khayashida@northwell.edu
Public contact
Name of contact person
| 1st name | Kei |
| Middle name | |
| Last name | Hayashida |
Organization
Feinstein Institutes for Medical Research
Division name
Laboratory for Critical Care Physiology
Zip code
11030
Address
350 Community Dr, Manhasset, NY
TEL
1-516-562-1305
Homepage URL
keilinda0714@gmail.com
Sponsor or person
Institute
Feinstein Institutes for Medical Research
Institute
Department
Personal name
Funding Source
Organization
Feinstein Institutes for Medical Research
Organization
Division
Category of Funding Organization
Outside Japan
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Feinstein Institutes for Medical Research
Address
350 Community Drive, Manhasset, NY
Tel
1-516-562-1305
keilinda0714@gmail.com
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2024 | Year | 09 | Month | 06 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2024 | Year | 09 | Month | 06 | Day |
Date of IRB
Anticipated trial start date
| 2024 | Year | 09 | Month | 06 | Day |
Last follow-up date
| 2025 | Year | 09 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Systematic review
Management information
Registered date
| 2024 | Year | 09 | Month | 06 | Day |
Last modified on
| 2024 | Year | 09 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000063350
